Atıf Formatları
Sirolimus is effective and safe in childhood relapsed-refractory autoimmune cytopenias: A multicentre study
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

S. OKUR ACAR Et Al. , "Sirolimus is effective and safe in childhood relapsed-refractory autoimmune cytopenias: A multicentre study," Scandinavian Journal of Immunology , vol.100, no.2, 2024

OKUR ACAR, S. Et Al. 2024. Sirolimus is effective and safe in childhood relapsed-refractory autoimmune cytopenias: A multicentre study. Scandinavian Journal of Immunology , vol.100, no.2 .

OKUR ACAR, S., Tahta, N., Al, I. O., Erdem, M., Gözmen, S., Karapınar, T. H., ... Kılınç, B.(2024). Sirolimus is effective and safe in childhood relapsed-refractory autoimmune cytopenias: A multicentre study. Scandinavian Journal of Immunology , vol.100, no.2.

OKUR ACAR, SULTAN Et Al. "Sirolimus is effective and safe in childhood relapsed-refractory autoimmune cytopenias: A multicentre study," Scandinavian Journal of Immunology , vol.100, no.2, 2024

OKUR ACAR, SULTAN O. Et Al. "Sirolimus is effective and safe in childhood relapsed-refractory autoimmune cytopenias: A multicentre study." Scandinavian Journal of Immunology , vol.100, no.2, 2024

OKUR ACAR, S. Et Al. (2024) . "Sirolimus is effective and safe in childhood relapsed-refractory autoimmune cytopenias: A multicentre study." Scandinavian Journal of Immunology , vol.100, no.2.

@article{article, author={SULTAN OKUR ACAR Et Al. }, title={Sirolimus is effective and safe in childhood relapsed-refractory autoimmune cytopenias: A multicentre study}, journal={Scandinavian Journal of Immunology}, year=2024}